Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that by 2014 Shire Pharmaceutical's novel agent, NRP-104, will be the first drug to achieve blockbuster status for the treatment of attention-deficit hyperactivity disorder (ADHD).

The new Pharmacor report entitled Attention-Deficit Hyperactivity Disorder, finds that although companies such as Predix, DOV Pharmaceuticals, and Cortex are attempting to develop novel therapies for attention-deficit hyperactivity disorder, physicians interviewed agree that none of these agents are likely to possess the efficacy of the psychostimulants methylphenidate and amphetamine and therefore are unlikely to launch during the next ten years.

"Not only will Shire have a blockbuster agent, but the company will own a majority of the market," said Anathea Waitekus, analyst at Decision Resources, Inc. "We forecast that the ADHD market will grow to $4.6 billion by 2014 and approximately half of the sales share of ADHD drugs will be attributed to six therapies owned by Shire. These drugs include Adderall, Adderall XR, and their novel agent with an improved safety profile, NRP-104."

About ADHD

The symptoms of ADHD include inattention and/or hyperactivity-impulsivity that have persisted for at least six months to a degree that is inconsistent with the individual's developmental level. ADHD often goes undiagnosed because its symptoms may emerge differently throughout the lifecycle with persistence of inattention and remission of hyperactivity-impulsivity in the adult years. ADHD is increasingly being diagnosed and treated in adults as physicians have discovered that the long-term negative impact of the disease can be severe.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Launch of New Drugs From Bayer and Boehringer Ingelheim will Generate Robust Growth in the Anticoagulant Market

View Now